← Browse by Condition
Medical Condition

smouldering myeloma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06762769 Phase 2
Recruiting

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Enrollment
63 pts
Location
United Kingdom
Sponsor
University College, London
View Trial →